These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30526674)

  • 1. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
    Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
    Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
    Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
    Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography.
    Joo I; Lee JM; Lee DH; Ahn SJ; Lee ES; Han JK
    J Magn Reson Imaging; 2017 Mar; 45(3):731-740. PubMed ID: 27474328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
    Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
    Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.
    Kwag M; Choi SH; Choi SJ; Byun JH; Won HJ; Shin YM
    Radiology; 2022 Dec; 305(3):614-622. PubMed ID: 35972362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtraction Images From Portal Venous Phase Gadoxetic Acid-Enhanced MRI for Observing Washout and Enhancing Capsule Features in LI-RADS Version 2018.
    Chung JW; Yu JS; Choi JM; Cho ES; Kim JH; Chung JJ
    AJR Am J Roentgenol; 2020 Jan; 214(1):72-80. PubMed ID: 31573851
    [No Abstract]   [Full Text] [Related]  

  • 8. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS.
    Hwang SH; Park S; Han K; Choi JY; Park YN; Park MS
    Abdom Radiol (NY); 2019 Sep; 44(9):3078-3088. PubMed ID: 31165907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.
    Joo I; Lee JM; Lee SM; Lee JS; Park JY; Han JK
    J Magn Reson Imaging; 2016 Nov; 44(5):1330-1338. PubMed ID: 27087012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
    Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
    Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.
    Lee S; Kim SS; Bae H; Shin J; Yoon JK; Kim MJ
    Eur Radiol; 2021 Feb; 31(2):855-863. PubMed ID: 32809162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
    Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
    Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging?
    Kim YK; Kim CS; Han YM; Park G
    Invest Radiol; 2010 Nov; 45(11):740-6. PubMed ID: 20644488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
    Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
    Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.
    Min JH; Kim JM; Kim YK; Kang TW; Lee SJ; Choi GS; Choi SY; Ahn S
    Hepatology; 2018 Dec; 68(6):2254-2266. PubMed ID: 30070365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver imaging reporting and data system diagnostic performance in hepatocellular carcinoma when modifying the definition of "washout" on gadoxetic acid-enhanced magnetic resonance imaging.
    Hu W; Lyu R; Wang D; Gao Z; Sun C; Jia K
    Arab J Gastroenterol; 2024 Feb; 25(1):58-63. PubMed ID: 38245474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
    De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.